Baxter is facing considerable challenges due to tariffs imposed on trade between the U.S. and China. While only a small portion of Baxter's sales are in China, these tariffs have a dramatic effect, accounting for nearly half of the company's total impact. In response, Baxter is considering various strategies to lessen the financial burden, such as increasing inventory and seeking alternative suppliers. The broader healthcare sector is also affected, with companies like GE Healthcare and Abbott Laboratories forecasting significant costs due to the tariffs, highlighting vulnerabilities in the healthcare supply chain exposed by the pandemic.
In general, the health care and medical sector, including hospitals, is bracing for price increases and shortages from the tariffs.
Baxter is now looking into ways to dampen the financial blow from the tariffs, including carrying additional inventory and identifying alternative suppliers.
Collection
[
|
...
]